Thymosin Alpha-1 Good price

The primary function of Thymosin Alpha-1

The primary pharmacological mechanism involves activating innate immunity to promote dendritic cell (DC) maturation and enhance antigen presentation capacity.

Activates natural killer (NK) cells and macrophages to enhance the clearance capacity against pathogens and tumor cells; regulates adaptive immunity to promote the differentiation of T cell precursors into mature T cells; and increases the quantity and activity of CD4 ⁺ and CD8 ⁺ T cells.

Promote the secretion of Th1-type cytokines (such as IFN- γ and IL-2) and enhance the cellular immune response

Moderately regulate regulatory T cells (Tregs) to maintain immune tolerance and avoid excessive immune responses

Enhances B-cell antibody secretion and improves vaccine response efficiency, with direct and indirect antiviral effects that inhibit the replication of various viruses including HBV, HCV, SARS-CoV-2, influenza virus, and HIV.

Reversion of virus-induced T-cell depletion and disruption of immune tolerance, when combined with interferon, exhibits synergistic antitumor effects that enhance the recognition and killing capacity of CD8 ⁺ T cells and NK cells against tumor cells.

Inhibit tumor proliferation, invasion, and angiogenesis, and induce tumor apoptosis

Reduce the damage caused by chemoradiotherapy to immune cells and the hematopoietic system, and enhance treatment tolerance

Combination with PD-1/PD-L1 inhibitors enhances the response rate to immunotherapy. Antioxidant and cell-protective effects include upregulation of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx), thereby mitigating oxidative stress damage.

Clinical Application Scenario

Chronic hepatitis B: As a first-line immunomodulatory adjuvant therapy to enhance HBV clearance rate

Tumor adjuvant therapy: Used in combination with chemotherapy, radiotherapy, and immunotherapy to enhance therapeutic efficacy and reduce adverse effects.

Immunocompromised status: Indicated for postoperative patients, elderly individuals, HIV-infected individuals, and other populations requiring restoration of immune function.

Infectious diseases: Adjuvant therapy for viral infections such as influenza and COVID-19, reducing disease duration

Vaccine booster: Enhances antibody responses to vaccines in elderly individuals and immunocompromised persons